NCI-designated Basic Laboratory Cancer Centers get research done—efficiently

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Having had the honor and pleasure to lead an NCI-designated cancer center for several years, I would like to share my thoughts on this small yet unique set of institutes and their value to NCI and the nation. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Ze’ev Ronai, PhD
Director, Translational Research Institute, Professor, Department of Biomedical Sciences and the Jim and Eleanor Randall Department of Surgery, Scientific director, Surgical Melanoma Research Program, Randall Department of Surgery, Cedars Sinai Medical Center
Table of Contents

YOU MAY BE INTERESTED IN

In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 
Ze’ev Ronai, PhD
Director, Translational Research Institute, Professor, Department of Biomedical Sciences and the Jim and Eleanor Randall Department of Surgery, Scientific director, Surgical Melanoma Research Program, Randall Department of Surgery, Cedars Sinai Medical Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login